Cargando…

Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study

BACKGROUND AND OBJECTIVE: The long term effects of fingolimod, an oral treatment for relapsing-remitting (RR) multiple sclerosis (MS), on blood circulating B and T cell subtypes in MS patients are not completely understood. This study describes for the first time the longitudinal effects of fingolim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Claes, Nele, Dhaeze, Tessa, Fraussen, Judith, Broux, Bieke, Van Wijmeersch, Bart, Stinissen, Piet, Hupperts, Raymond, Hellings, Niels, Somers, Veerle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215872/ https://www.ncbi.nlm.nih.gov/pubmed/25360562 http://dx.doi.org/10.1371/journal.pone.0111115

Ejemplares similares

B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions
por: Claes, Nele, et al.
Publicado: (2015)

Cytotoxic CD4+ T Cells Drive Multiple Sclerosis Progression
por: Peeters, Liesbet M., et al.
Publicado: (2017)

Cytomegalovirus infection exacerbates autoimmune mediated neuroinflammation
por: Vanheusden, Marjan, et al.
Publicado: (2017)

CNS delivery of anti-CD52 antibodies modestly reduces disease severity in an animal model for multiple sclerosis
por: Bogie, Jeroen FJ, et al.
Publicado: (2020)

Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients
por: Montes Diaz, G., et al.
Publicado: (2018)

Treg-Resistant Cytotoxic CD4(+) T Cells Dictate T Helper Cells in Their Vicinity: TH17 Skewing and Modulation of Proliferation
por: Hoeks, Cindy, et al.
Publicado: (2021)

Oncostatin M, an Underestimated Player in the Central Nervous System
por: Houben, Evelien, et al.
Publicado: (2019)

Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions
por: Muris, Anne-Hilde, et al.
Publicado: (2014)

When Helpers Go Above and Beyond: Development and Characterization of Cytotoxic CD4(+) T Cells
por: Hoeks, Cindy, et al.
Publicado: (2022)

B cell characterization and reactivity analysis in multiple sclerosis
por: Fraussen, J., et al.
Publicado: (2009)

Relapsing-remitting multiple sclerosis patients display an altered lipoprotein profile with dysfunctional HDL
por: Jorissen, Winde, et al.
Publicado: (2017)

Frameshifting in the P6 cDNA Phage Display System
por: Govarts, Cindy, et al.
Publicado: (2010)

Editorial: Neuro-Immune Connections to Enable Repair in CNS Disorders
por: Vanmierlo, Tim, et al.
Publicado: (2020)

Comprehensive antibody and cytokine profiling in hospitalized COVID-19 patients in relation to clinical outcomes in a large Belgian cohort
por: Ruytinx, Pieter, et al.
Publicado: (2023)

Improving the Efficacy of Regulatory T Cell Therapy
por: Baeten, Paulien, et al.
Publicado: (2021)

Myelin-phagocytosing macrophages modulate autoreactive T cell proliferation
por: Bogie, Jeroen FJ, et al.
Publicado: (2011)

Machine learning analysis of motor evoked potential time series to predict disability progression in multiple sclerosis
por: Yperman, Jan, et al.
Publicado: (2020)

Regulatory T cell therapy for multiple sclerosis: Breaching (blood-brain) barriers
por: Verreycken, Janne, et al.
Publicado: (2022)

Peripheral blood but not synovial fluid natural killer T cells are biased towards a Th1-like phenotype in rheumatoid arthritis
por: Linsen, Loes, et al.
Publicado: (2005)

The isotype repertoire of antibodies against novel UH-RA peptides in rheumatoid arthritis
por: De Winter, Liesbeth M., et al.
Publicado: (2016)

Interrelation of Diet, Gut Microbiome, and Autoantibody Production
por: Petta, Ioanna, et al.
Publicado: (2018)

Innate Lymphoid Cells - Neglected Players in Multiple Sclerosis
por: Sadeghi Hassanabadi, Negar, et al.
Publicado: (2022)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Twelve Weeks of Medium-Intensity Exercise Therapy Affects the Lipoprotein Profile of Multiple Sclerosis Patients
por: Jorissen, Winde, et al.
Publicado: (2018)

A novel method for making human monoclonal antibodies
por: Fraussen, J., et al.
Publicado: (2010)

Identification of Protein Networks Involved in the Disease Course of Experimental Autoimmune Encephalomyelitis, an Animal Model of Multiple Sclerosis
por: Vanheel, Annelies, et al.
Publicado: (2012)

Label-Free Imaging of Umbilical Cord Tissue Morphology and Explant-Derived Cells
por: Donders, Raf, et al.
Publicado: (2016)

Editorial: New Insights Into B Cell Subsets in Health and Disease
por: Somers, Veerle, et al.
Publicado: (2022)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Local Overexpression of Interleukin-11 in the Central Nervous System Limits Demyelination and Enhances Remyelination
por: Maheshwari, Anurag, et al.
Publicado: (2013)

L-Arginine Depletion Improves Spinal Cord Injury via Immunomodulation and Nitric Oxide Reduction
por: Erens, Céline, et al.
Publicado: (2022)

Raising to the Challenge: Building a Federated Biobank to Accelerate Translational Research—The University Biobank Limburg
por: Linsen, Loes, et al.
Publicado: (2019)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis
por: Ohtani, Ryohei, et al.
Publicado: (2018)

Fingolimod-Associated Macular Edema in the Treatment of Multiple Sclerosis
por: Khan, Asma A, et al.
Publicado: (2023)

Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011)

Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients
por: Marriott, James J.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_nrnqmdh5g2meti5drs5g63933i